Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
Year: 2009
Type: review
Abstract: The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review.
Source: Molecular Cancer Therapeutics
Authors: Nathan T. Ihle, Garth Powis
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funder: National Cancer Institute
Awards: CANCER DRUGS ACTIVE AGAINST SIGNAL TRANSDUCTION TARGETS, Novel Inhibitors of Akt Signaling in Pancreatic Cancer, G2914803525, Therapeutic Targeting of Hypoxic and Oxidative Stress, Cancer Drugs Active Against Stress Signaling Pathways, G521726118, Specialized Program Research Excellence (SPORE) in Gastrointestinal Cancer
OpenAlex ID: W2161437969
